← Leaderboards
Tanya Pamela Garcia
Texas A&M University Health Science Ctr
$2,469,567
Attributed
$2,469,567
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $789.4K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,469,567 · 2
By mechanism
R01$1,730,255 · 1
K01$739,312 · 1
Top collaborators
No co-investigators on record.
Most similar at Texas A&M University Health Science Ctr
Same institution · by research overlap
- Nathan N Alder$4,561,620
- Amanda H. Mahnke$404,127
Others in their field
Other Emerging Leaders on “Motor”
- James Dale Berry · Brigham And Women'S Hospital$16,144,018
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Shadi Dayeh · University Of California, San Diego$13,862,272
- Carla M Bann · Research Triangle Institute$12,326,135
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- Afonso C Silva · University Of Pittsburgh At Pittsburgh$11,554,502
Research focus
MotorClinical TrialsClinical Trials DesignLeadData SetResearch PersonnelStatistical ModelsUnited States National Institutes Of HealthHuntington DiseaseNeurodegenerative DisordersSymptomsMeasurementPreventScienceFundingClinical DiagnosisGeneticScientistOpen SourceDesignSource CodeCohortAreaLongitudinal Dataset
Grant awards (12)
Developing a Robust and Efficient Strategy for Censored Covariates to Improve Clinical Trial Design for Neurodegenerative Diseases$455,253
R01 · FY2025 · NS · contact PI
Developing a Robust and Efficient Strategy for Censored Covariates to Improve Clinical Trial Design for Neurodegenerative Diseases$441,595
R01 · FY2024 · NS · contact PI
Landis Award for Outstanding Mentorship: Administrative Supplement to NS131225$155,500
R01 · FY2024 · NS · contact PI
Developing a Robust and Efficient Strategy for Censored Covariates to Improve Clinical Trial Design for Neurodegenerative Diseases$77,427
R01 · FY2024 · NS · contact PI
Diversity Supplement: Developing a robust and efficient strategy for censored covariates to improve clinical trial design for neurodegenerative diseases$42,334
R01 · FY2024 · NS · contact PI
Developing a Robust and Efficient Strategy for Censored Covariates to Improve Clinical Trial Design for Neurodegenerative Diseases$38,760
R01 · FY2024 · NS · contact PI
Diversity Supplement: Developing a robust and efficient strategy for censored covariates to improve clinical trial design for neurodegenerative diseases$33,818
R01 · FY2024 · NS · contact PI
Developing a Robust and Efficient Strategy for Censored Covariates to Improve Clinical Trial Design for Neurodegenerative Diseases$485,568
R01 · FY2023 · NS · contact PI
Innovative Statistical Models for Development of First HuntingtonÃÂâÃÂÃÂÃÂÃÂs Disease Progression Risk Assessment Tool$181,906
K01 · FY2019 · NS · contact PI
Innovative Statistical Models for Development of First Huntington's Disease Progression Risk Assessment Tool$181,906
K01 · FY2019 · NS · contact PI
Innovative Statistical Models for Development of First Huntington's Disease Progression Risk Assessment Tool$184,703
K01 · FY2018 · NS · contact PI
Innovative Statistical Models for Development of First Huntington's Disease Progression Risk Assessment Tool$190,797
K01 · FY2017 · NS · contact PI